| Trial ID: | L0039 |
| Source ID: | NCT01277094
|
| Associated Drug: |
RO5093151
|
| Title: |
A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD
|
| Interventions: |
Drug: Placebo|Drug: RO5093151
|
| Outcome Measures: |
Change of liver fat content measured by magnetic resonance spectroscopy (MRS)|Change in insulin resistance assessed by hyperinsulinemic euglycemic clamp|Change in endogenous glucose production assessed by hyperinsulinemic euglycemic clamp|Pharmacokinetic measures (max and min concentration, clearance, half-life, etc)|Safety (incidence and nature of adverse events)
|
| Sponsor/Collaborators: |
Hoffmann-La Roche
|
| Gender: |
All
|
| Age: |
35 Years to 65 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
82
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
|
| Start Date: |
April 2011
|
| Completion Date: |
March 2012
|
| Results First Posted: |
--
|
| Last Update Posted: |
November 2, 2016
|
| Locations: |
Wien, Austria|Dusseldorf, Germany|Nuthetal, Germany|T??bingen, Germany
|
| URL: |
https://ClinicalTrials.gov/show/NCT01277094
|
